Intact Investment Management Inc. Boosts Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Intact Investment Management Inc. raised its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 66.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,000 shares of the medical device company's stock after acquiring an additional 8,000 shares during the quarter. Intact Investment Management Inc.'s holdings in DexCom were worth $1,366,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Private Trust Co. NA increased its holdings in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after purchasing an additional 245 shares during the period. Optiver Holding B.V. bought a new position in shares of DexCom in the fourth quarter worth $33,000. TD Private Client Wealth LLC increased its holdings in shares of DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after purchasing an additional 167 shares during the period. Larson Financial Group LLC increased its holdings in shares of DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after purchasing an additional 137 shares during the period. Finally, Heck Capital Advisors LLC bought a new position in shares of DexCom in the fourth quarter worth $38,000. Institutional investors own 97.75% of the company's stock.

DexCom Trading Down 0.2%

NASDAQ DXCM traded down $0.16 during trading on Monday, hitting $79.84. 5,672,329 shares of the company's stock traded hands, compared to its average volume of 4,361,759. The stock has a fifty day moving average of $80.33 and a two-hundred day moving average of $79.41. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $117.19. The firm has a market cap of $31.31 billion, a P/E ratio of 59.58, a PEG ratio of 1.71 and a beta of 1.46.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The business had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. During the same quarter in the previous year, the company earned $0.32 earnings per share. The business's quarterly revenue was up 12.5% on a year-over-year basis. As a group, sell-side analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Wall Street Zen raised shares of DexCom from a "hold" rating to a "buy" rating in a report on Saturday. Truist Financial assumed coverage on shares of DexCom in a report on Monday, June 16th. They issued a "buy" rating and a $102.00 price target on the stock. The Goldman Sachs Group assumed coverage on shares of DexCom in a report on Friday, May 30th. They issued a "buy" rating and a $104.00 price target on the stock. Barclays upped their price target on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a report on Monday, May 5th. Finally, Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Four investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $98.50.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 6,184 shares of the stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total transaction of $526,320.24. Following the completion of the sale, the executive vice president now directly owns 109,621 shares in the company, valued at approximately $9,329,843.31. This represents a 5.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michael Jon Brown sold 10,000 shares of the stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $84.28, for a total transaction of $842,800.00. Following the sale, the executive vice president now owns 95,602 shares of the company's stock, valued at approximately $8,057,336.56. This represents a 9.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 25,724 shares of company stock worth $2,157,034 over the last three months. Company insiders own 0.32% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.